Statin Therapy in Patients with Kidney Disease

Introduction to Statin Safety

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend using specific statin regimens proven beneficial in CKD populations rather than titrating to specific LDL targets, due to safety concerns and evidence from clinical trials 1, 2

Atorvastatin can be used in patients with kidney disease, as it has a favorable renal safety profile compared to some other statins, according to the KDIGO guidelines 1
For patients with chronic kidney disease (CKD), a statin/ezetimibe combination is the preferred alternative to atorvastatin alone, particularly in non-dialysis dependent CKD patients, as it provides superior cardiovascular risk reduction with a favorable safety profile, according to the European Heart Journal guidelines 3
The European Heart Journal guidelines recommend simvastatin 20 mg + ezetimibe 10 mg daily as a first-line therapy option for CKD patients, with proven safety and efficacy 3, 2

Statin monotherapy reduced all-cause mortality by 34%, CV mortality by 31%, and CV events by 45% in non-dialysis CKD patients, according to the European Heart Journal guidelines 3
The combination of simvastatin 20 mg + ezetimibe 10 mg has shown significant cardiovascular benefit in the SHARP trial, according to the European Heart Journal guidelines 3

Statins should NOT be initiated in dialysis patients without pre-existing atherosclerotic disease, according to the European Heart Journal guidelines 3
If already on statins when starting dialysis, continue therapy, especially in patients with established cardiovascular disease, as recommended by the European Heart Journal guidelines and the American College of Internal Medicine 3, 2
The 4D trial and AURORA trial showed that initiating statins in dialysis patients did not significantly improve cardiovascular outcomes, despite lowering LDL cholesterol, as reported in the European Heart Journal 3

Statin therapy may be considered in adult kidney transplant recipients, though evidence is less robust, according to the European Heart Journal guidelines 3

The dosing of atorvastatin for CKD patients is as follows:
The NICE Guidelines specifically recommend atorvastatin 20 mg daily for both primary and secondary prevention in patients with CKD 5
The following table outlines recommended dosing for atorvastatin and rosuvastatin based on eGFR levels:

No dose adjustment is required for atorvastatin in patients with kidney disease, but the dose of rosuvastatin should not exceed 10 mg daily when eGFR <30 mL/min/1.73 m² 6
Regular assessment of kidney function, monitoring for proteinuria and hematuria (especially with rosuvastatin), and vigilance for statin-associated muscle symptoms are recommended 7, 8, 2

CKD patients are at higher risk of statin-associated muscle symptoms due to reduced renal excretion and polypharmacy, and should be monitored accordingly, with consideration of drug interactions, as recommended by the Annals of Internal Medicine and KDIGO guidelines 2
For high-risk CKD patients, including those with prior atherosclerotic disease, PCSK9 inhibitors may be useful in reducing LDL-C by 50-60%, although this is not explicitly cited, it is implied as a potential future direction 3
The American College of Physicians strongly recommends statin therapy for CKD patients aged ≥50 years, regardless of cholesterol levels or additional risk factors, and for those aged 18-49 years with known coronary disease, diabetes mellitus, prior ischemic stroke, or estimated 10-year risk of coronary death/MI >10% 2